NDC 42023-233

Corphedra

Ephedrine Sulfate

Corphedra is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Par Pharmaceutical, Inc.. The primary component is Ephedrine Sulfate.

Product ID42023-233_aa6213f5-e549-4e42-a795-b791de8353b7
NDC42023-233
Product TypeHuman Prescription Drug
Proprietary NameCorphedra
Generic NameEphedrine Sulfate
Dosage FormInjection, Solution
Route of AdministrationINTRAVENOUS
Marketing Start Date2019-01-18
Marketing CategoryNDA /
Application NumberNDA208943
Labeler NamePar Pharmaceutical, Inc.
Substance NameEPHEDRINE SULFATE
Active Ingredient Strength500 mg/10mL
Pharm ClassesAdrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Increased Norepinephrine Activity [PE], Norepinephrine Releasing Agent [EPC], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC]
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 42023-233-01

10 mL in 1 VIAL (42023-233-01)
Marketing Start Date2019-01-18
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "Corphedra" or generic name "Ephedrine Sulfate"

NDCBrand NameGeneric Name
42023-196CorphedraEphedrine Sulfate
42023-233Corphedraephedrine sulfate
14789-250EmerphedEphedrine Sulfate
0143-3145Ephedrine SulfateEphedrine Sulfate
0363-5789Ephedrine SulfateEphedrine Sulfate
0641-6238Ephedrine SulfateEphedrine Sulfate
0781-3269Ephedrine SulfateEphedrine Sulfate
14789-014Ephedrine SulfateEphedrine Sulfate
16714-037Ephedrine SulfateEphedrine Sulfate
17478-415Ephedrine SulfateEphedrine Sulfate
17478-515Ephedrine SulfateEphedrine Sulfate
17478-517Ephedrine SulfateEphedrine Sulfate
17478-955Ephedrine SulfateEphedrine Sulfate
42023-216Ephedrine SulfateEphedrine Sulfate
42023-243EPHEDRINE SULFATEEphedrine Sulfate
42023-253EPHEDRINE SULFATEEphedrine Sulfate
43598-725Ephedrine sulfateEphedrine sulfate

Trademark Results [Corphedra]

Mark Image

Registration | Serial
Company
Trademark
Application Date
CORPHEDRA
CORPHEDRA
86921301 not registered Dead/Abandoned
PAR PHARMACEUTICAL, INC.
2016-02-26

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.